Brazil enters a terrifying scenario

With that, The moving average of deaths in Brazil last week reached 2,234, another record high in the coronavirus pandemic index.

Compared to the average of 14 days ago, the change was + 49%, indicating an upward trend in deaths from the disease.

This is, according to specialists and statisticians, the highest number of deaths recorded on a Saturday since the start of the pandemic, exceeding the record last Saturday (March 13), where 1,940 deaths were counted.

There are already 59 days in a row with the moving average of deaths above the 1000 mark, and for the thirteenth day the mark appears above 1500.

The analysis of the figures contains more elements of fear, since Last Friday, for the first time since the start of the coronavirus pandemic, Brazil hit the 15,000 death mark in one week.

Brazil Coronavirus

Photo: Reuters

The Brazilian President, Jair Bolsonaro, appointed new Minister of Health – the fourth in just under a year – the cardiologist Marcelo Queiroga, who so far has only made two public appearances.

He said he would seek to agree on “some additional measures to which they have been applied”, on which he has not elaborated, and has defended social distancing or the use of chin straps, which are openly rejected by Bolsonaro.

The health system is collapsing, with 80% of the occupancy of intensive care beds at the federal level, a percentage that reaches 100% in the states bordering Argentina.

In St.Paul, Brazil’s largest city, patients are being evacuated due to lack of beds and space to breathe. This week, the first death was on record so that it could not be admitted.

Yesterday, 11,721,357 people already received the first dose of the coronavirus vaccine. The number represents only 5.54% of Brazil’s population.

According to a Datafolha poll, published this Sunday, 84% of the population want to be vaccinated against the coronavirus throughout Brazil.

So far, the Bolsonaro government has struggled to stock up on vaccines. This Sunday, he received bad news from the Serum Institute of India (SII) about a delay in deliveries of the vaccine manufactured under license from AstraZeneca due to strong internal demand.